Reuters logo
BRIEF-Neurotech announces positive Phase 2 results in NT-501 (CNTF)
June 20, 2017 / 1:40 PM / 3 months ago

BRIEF-Neurotech announces positive Phase 2 results in NT-501 (CNTF)

June 20 (Reuters) - Neurotech International Ltd

* Neurotech announces positive phase 2 results in nt-501 (cntf) for macular telangiectasia

* Neurotech international ltd - nt-501 was generally well tolerated, consistent with previous studies of nt-501 in retinitis pigmentosa and dry amd

* Neurotech international - majority of adverse events were related to surgical procedure; all cases surgery-related events were resolved within 3 months

* Neurotech international ltd - no participants had implant removed during course of study

* Neurotech international ltd - planning to initiate phase 3 program by end of the year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below